WallStreetZenWallStreetZen

NASDAQ: IMNN
Imunon Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IMNN

Based on 1 analyst offering 12 month price targets for Imunon Inc

Min Forecast
$10.00+532.91%
Avg Forecast
$10.00+532.91%
Max Forecast
$10.00+532.91%

Should I buy or sell IMNN stock?

Based on 1 analyst offering ratings for Imunon Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IMNN stock forecasts and price targets.

IMNN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-17

1 of 1

Forecast return on equity

Is IMNN forecast to generate an efficient return?

Company
-277.38%
Industry
15.5%
Market
167.6%
IMNN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMNN forecast to generate an efficient return on assets?

Company
-77.52%
Industry
23.42%
IMNN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMNN earnings per share forecast

What is IMNN's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$2.16
Avg 2 year Forecast
-$1.79
Avg 3 year Forecast
-$1.89

IMNN revenue forecast

What is IMNN's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

IMNN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMNN$1.58$10.00+532.91%Strong Buy
ENSC$0.46N/AN/A
TRAW$0.55$1.00+81.82%Hold
CNSP$5.73N/AN/A
SNGX$0.38N/AN/A
View Top Biotech Stocks

Imunon Stock Forecast FAQ

Is Imunon Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IMNN) stock is to Strong Buy IMNN stock.

Out of 1 analyst, 1 (100%) are recommending IMNN as a Strong Buy, 0 (0%) are recommending IMNN as a Buy, 0 (0%) are recommending IMNN as a Hold, 0 (0%) are recommending IMNN as a Sell, and 0 (0%) are recommending IMNN as a Strong Sell.

If you're new to stock investing, here's how to buy Imunon stock.

What is IMNN's earnings growth forecast for 2026-2028?

(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.05%.

Imunon's earnings in 2026 is -$14,733,162.On average, 7 Wall Street analysts forecast IMNN's earnings for 2026 to be -$12,120,069, with the lowest IMNN earnings forecast at -$15,892,616, and the highest IMNN earnings forecast at -$6,245,492. On average, 7 Wall Street analysts forecast IMNN's earnings for 2027 to be -$10,016,354, with the lowest IMNN earnings forecast at -$16,662,500, and the highest IMNN earnings forecast at -$4,301,140.

In 2028, IMNN is forecast to generate -$10,603,307 in earnings, with the lowest earnings forecast at -$16,497,525 and the highest earnings forecast at -$7,129,288.

What is IMNN's revenue growth forecast for 2026-2028?

(NASDAQ: IMNN) Imunon's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.43%.

Imunon's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast IMNN's revenue for 2026 to be $0, with the lowest IMNN revenue forecast at $0, and the highest IMNN revenue forecast at $0. On average, 6 Wall Street analysts forecast IMNN's revenue for 2027 to be $0, with the lowest IMNN revenue forecast at $0, and the highest IMNN revenue forecast at $0.

In 2028, IMNN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is IMNN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IMNN) forecast ROA is -77.52%, which is lower than the forecast US Biotechnology industry average of 23.42%.

What is IMNN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IMNN price target, the average IMNN price target is $10.00, with the highest IMNN stock price forecast at $10.00 and the lowest IMNN stock price forecast at $10.00.

The Wall Street analyst predicted that Imunon's share price could reach $10.00 by Apr 17, 2027. The average Imunon stock price prediction forecasts a potential upside of 532.91% from the current IMNN share price of $1.58.

What is IMNN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IMNN) Imunon's current Earnings Per Share (EPS) is -$3.84. On average, analysts forecast that IMNN's EPS will be -$2.16 for 2026, with the lowest EPS forecast at -$2.83, and the highest EPS forecast at -$1.11. On average, analysts forecast that IMNN's EPS will be -$1.79 for 2027, with the lowest EPS forecast at -$2.97, and the highest EPS forecast at -$0.77. In 2028, IMNN's EPS is forecast to hit -$1.89 (min: -$2.94, max: -$1.27).

What is IMNN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IMNN) forecast ROE is -277.38%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.